Tokyo, Jan. 30 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060506) titled 'Human studies on the immune function of Sendan alpha' on Jan. 29.
Study Type:
Interventional
Study Design:
Basic Design - Parallel
Randomization - Randomized
Blinding - Double blind -all involved are blinded
Control - Placebo
Primary Sponsor:
Institute - Southen Knight' Laboratory Co., Ltd.
Condition:
Condition - Healthy people
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - Sendan alpha is a product containing extracts derived from the plant Melia azedarach, and has been shown to have potent anti-cancer activity in human tumor cells and in mouse and dog tumor mo...